William Samuel David, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electromyography | 16 | 2017 | 1379 | 1.960 |
Why?
|
| Botulism | 2 | 2015 | 21 | 1.110 |
Why?
|
| Amyotrophic Lateral Sclerosis | 16 | 2021 | 1362 | 1.050 |
Why?
|
| Ulnar Neuropathies | 2 | 2012 | 33 | 0.840 |
Why?
|
| Neurophysiology | 1 | 2019 | 102 | 0.680 |
Why?
|
| Myasthenia Gravis | 4 | 2021 | 191 | 0.640 |
Why?
|
| Nerve Compression Syndromes | 1 | 2019 | 163 | 0.640 |
Why?
|
| Dyspnea | 2 | 2015 | 1256 | 0.630 |
Why?
|
| Spinal Nerve Roots | 1 | 2017 | 136 | 0.620 |
Why?
|
| Cystinosis | 3 | 2022 | 25 | 0.620 |
Why?
|
| Neuromuscular Diseases | 3 | 2015 | 262 | 0.590 |
Why?
|
| Muscle Weakness | 9 | 2019 | 406 | 0.580 |
Why?
|
| Neuralgia | 2 | 2019 | 520 | 0.560 |
Why?
|
| Muscle, Skeletal | 12 | 2019 | 4993 | 0.550 |
Why?
|
| Motor Neurons | 5 | 2021 | 812 | 0.540 |
Why?
|
| Peripheral Nervous System Diseases | 5 | 2019 | 703 | 0.520 |
Why?
|
| Muscular Diseases | 5 | 2020 | 559 | 0.470 |
Why?
|
| Ganglion Cysts | 1 | 2012 | 23 | 0.470 |
Why?
|
| Lower Extremity | 2 | 2019 | 1069 | 0.470 |
Why?
|
| Myositis, Inclusion Body | 3 | 2021 | 144 | 0.460 |
Why?
|
| Mononeuropathies | 1 | 2012 | 15 | 0.460 |
Why?
|
| Wrist | 2 | 2019 | 216 | 0.440 |
Why?
|
| Quadriceps Muscle | 1 | 2012 | 128 | 0.410 |
Why?
|
| Rhabdomyolysis | 1 | 2012 | 154 | 0.410 |
Why?
|
| Myography | 3 | 2018 | 105 | 0.390 |
Why?
|
| Polyneuropathies | 4 | 2022 | 134 | 0.370 |
Why?
|
| Simvastatin | 1 | 2012 | 359 | 0.360 |
Why?
|
| Spastic Paraplegia, Hereditary | 2 | 2009 | 131 | 0.360 |
Why?
|
| Electric Stimulation | 3 | 2011 | 1783 | 0.350 |
Why?
|
| Deglutition Disorders | 4 | 2022 | 578 | 0.350 |
Why?
|
| Neurology | 4 | 2022 | 746 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 1308 | 0.330 |
Why?
|
| Evoked Potentials, Motor | 4 | 2018 | 432 | 0.320 |
Why?
|
| Hypesthesia | 2 | 2017 | 103 | 0.320 |
Why?
|
| Hereditary Sensory and Autonomic Neuropathies | 2 | 2019 | 39 | 0.310 |
Why?
|
| Electric Impedance | 3 | 2018 | 655 | 0.310 |
Why?
|
| Neural Conduction | 5 | 2019 | 481 | 0.310 |
Why?
|
| Superoxide Dismutase | 1 | 2009 | 603 | 0.310 |
Why?
|
| Vocal Cord Paralysis | 1 | 2009 | 251 | 0.300 |
Why?
|
| Diagnosis, Differential | 11 | 2019 | 13276 | 0.290 |
Why?
|
| GTP Phosphohydrolases | 1 | 2009 | 516 | 0.290 |
Why?
|
| Facial Paralysis | 1 | 2009 | 327 | 0.280 |
Why?
|
| Diagnostic Techniques, Neurological | 2 | 2017 | 58 | 0.270 |
Why?
|
| Immunologic Factors | 3 | 2021 | 1575 | 0.270 |
Why?
|
| Status Asthmaticus | 2 | 2008 | 22 | 0.270 |
Why?
|
| Electrodiagnosis | 2 | 2003 | 152 | 0.270 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 900 | 0.270 |
Why?
|
| Rabbits | 2 | 2010 | 5143 | 0.260 |
Why?
|
| Distal Myopathies | 2 | 2020 | 15 | 0.250 |
Why?
|
| Ceftriaxone | 2 | 2014 | 150 | 0.240 |
Why?
|
| Arthrogryposis | 2 | 2019 | 74 | 0.230 |
Why?
|
| Carpal Tunnel Syndrome | 2 | 2003 | 274 | 0.230 |
Why?
|
| Pain | 5 | 2022 | 4692 | 0.210 |
Why?
|
| Phenylenediamines | 1 | 2021 | 91 | 0.200 |
Why?
|
| Myoglobinuria | 1 | 2000 | 24 | 0.200 |
Why?
|
| Radiography, Abdominal | 2 | 2015 | 580 | 0.190 |
Why?
|
| Hereditary Sensory and Motor Neuropathy | 1 | 2019 | 22 | 0.190 |
Why?
|
| Carbamates | 1 | 2021 | 199 | 0.180 |
Why?
|
| Genes, cdc | 1 | 2019 | 126 | 0.180 |
Why?
|
| Tibial Nerve | 1 | 2019 | 57 | 0.180 |
Why?
|
| Lumbosacral Plexus | 1 | 2019 | 54 | 0.180 |
Why?
|
| Fasciculation | 1 | 1998 | 8 | 0.180 |
Why?
|
| Hydroxylamines | 1 | 2018 | 42 | 0.170 |
Why?
|
| Lipodystrophy | 1 | 1999 | 146 | 0.170 |
Why?
|
| Diabetic Neuropathies | 1 | 2022 | 419 | 0.170 |
Why?
|
| Humans | 67 | 2022 | 717280 | 0.160 |
Why?
|
| Deficiency Diseases | 1 | 2017 | 73 | 0.160 |
Why?
|
| Creatine | 1 | 2019 | 418 | 0.160 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 1998 | 132 | 0.160 |
Why?
|
| Tarsal Tunnel Syndrome | 1 | 1996 | 8 | 0.160 |
Why?
|
| Paralysis | 1 | 1998 | 241 | 0.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 3130 | 0.160 |
Why?
|
| Double-Blind Method | 11 | 2021 | 11910 | 0.150 |
Why?
|
| Cryoglobulinemia | 1 | 1996 | 85 | 0.150 |
Why?
|
| Neuromuscular Junction Diseases | 1 | 2015 | 14 | 0.150 |
Why?
|
| Poliomyelitis | 1 | 1997 | 97 | 0.150 |
Why?
|
| Peripheral Nervous System | 1 | 2017 | 142 | 0.150 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2020 | 268 | 0.150 |
Why?
|
| Muscular Dystrophies | 2 | 2015 | 394 | 0.150 |
Why?
|
| 4-Aminopyridine | 1 | 2015 | 85 | 0.140 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 672 | 0.140 |
Why?
|
| Potassium Channel Blockers | 1 | 2015 | 175 | 0.140 |
Why?
|
| Sample Size | 1 | 2018 | 819 | 0.140 |
Why?
|
| Sciatic Nerve | 1 | 2019 | 623 | 0.140 |
Why?
|
| Orphan Drug Production | 1 | 2015 | 65 | 0.140 |
Why?
|
| Vital Capacity | 5 | 2019 | 912 | 0.130 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 295 | 0.130 |
Why?
|
| Action Potentials | 3 | 2011 | 1791 | 0.130 |
Why?
|
| Copper | 1 | 2017 | 389 | 0.130 |
Why?
|
| Clozapine | 1 | 1998 | 496 | 0.130 |
Why?
|
| Middle Aged | 33 | 2021 | 215054 | 0.130 |
Why?
|
| Serine | 1 | 2019 | 857 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2019 | 999 | 0.130 |
Why?
|
| Arthralgia | 1 | 2019 | 465 | 0.130 |
Why?
|
| Muscular Dystrophies, Limb-Girdle | 1 | 2014 | 66 | 0.130 |
Why?
|
| Female | 42 | 2021 | 377934 | 0.130 |
Why?
|
| Adult | 33 | 2022 | 212470 | 0.130 |
Why?
|
| Ankle | 1 | 1996 | 277 | 0.130 |
Why?
|
| Cerebrospinal Fluid | 1 | 2017 | 555 | 0.130 |
Why?
|
| Hyperlipidemias | 1 | 1999 | 805 | 0.130 |
Why?
|
| Anti-Asthmatic Agents | 1 | 1998 | 550 | 0.130 |
Why?
|
| Diplopia | 1 | 2015 | 181 | 0.120 |
Why?
|
| Voice Disorders | 1 | 1996 | 273 | 0.120 |
Why?
|
| Zinc | 1 | 2017 | 695 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 34503 | 0.120 |
Why?
|
| Vasculitis | 1 | 1996 | 518 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1850 | 0.110 |
Why?
|
| Ileus | 1 | 2012 | 59 | 0.110 |
Why?
|
| Spinal Cord | 1 | 2021 | 1823 | 0.110 |
Why?
|
| Muscle Strength | 3 | 2021 | 567 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1144 | 0.110 |
Why?
|
| Sarcoidosis | 1 | 2017 | 525 | 0.110 |
Why?
|
| Leg | 2 | 2012 | 1139 | 0.110 |
Why?
|
| Peripheral Nerves | 2 | 2009 | 465 | 0.100 |
Why?
|
| Hypoglossal Nerve | 1 | 2011 | 96 | 0.100 |
Why?
|
| Polysomnography | 1 | 1997 | 1749 | 0.100 |
Why?
|
| Neuroprotective Agents | 1 | 2018 | 1000 | 0.100 |
Why?
|
| Aged | 24 | 2021 | 162862 | 0.100 |
Why?
|
| Skin | 2 | 2015 | 4355 | 0.100 |
Why?
|
| Male | 36 | 2021 | 351399 | 0.100 |
Why?
|
| Disease Progression | 8 | 2020 | 13308 | 0.100 |
Why?
|
| Airway Remodeling | 1 | 2011 | 141 | 0.100 |
Why?
|
| Anterior Horn Cells | 1 | 2009 | 19 | 0.100 |
Why?
|
| Immunosuppressive Agents | 3 | 2020 | 4208 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2019 | 3513 | 0.090 |
Why?
|
| Methotrexate | 1 | 2016 | 1732 | 0.090 |
Why?
|
| Biological Dressings | 1 | 2009 | 32 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2015 | 1569 | 0.090 |
Why?
|
| Motor Neuron Disease | 1 | 2009 | 109 | 0.090 |
Why?
|
| Vaccines | 1 | 1997 | 735 | 0.090 |
Why?
|
| Biopsy | 3 | 2000 | 6753 | 0.090 |
Why?
|
| Photochemistry | 1 | 2009 | 246 | 0.090 |
Why?
|
| Central Nervous System Agents | 1 | 2008 | 77 | 0.080 |
Why?
|
| Abdominal Pain | 1 | 2015 | 1030 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2016 | 2405 | 0.080 |
Why?
|
| Disease Management | 1 | 2019 | 2538 | 0.080 |
Why?
|
| Receptors, Cholinergic | 2 | 2020 | 194 | 0.080 |
Why?
|
| Valine | 1 | 2009 | 427 | 0.080 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 1841 | 0.080 |
Why?
|
| Weight Loss | 1 | 2019 | 2495 | 0.080 |
Why?
|
| Amnion | 1 | 2009 | 206 | 0.080 |
Why?
|
| Syndrome | 2 | 2009 | 3201 | 0.080 |
Why?
|
| Respiration, Artificial | 3 | 2020 | 2467 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17432 | 0.080 |
Why?
|
| Chest Wall Oscillation | 1 | 2006 | 12 | 0.080 |
Why?
|
| Deep Sedation | 1 | 2008 | 114 | 0.080 |
Why?
|
| Treatment Outcome | 9 | 2021 | 62344 | 0.080 |
Why?
|
| Alanine | 1 | 2009 | 597 | 0.080 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2018 | 42 | 0.080 |
Why?
|
| Respiratory Function Tests | 3 | 2019 | 1671 | 0.080 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 16020 | 0.080 |
Why?
|
| Hepatitis C | 1 | 1996 | 1518 | 0.080 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2010 | 571 | 0.080 |
Why?
|
| Reference Values | 2 | 2010 | 5058 | 0.070 |
Why?
|
| Nerve Fibers | 1 | 2010 | 709 | 0.070 |
Why?
|
| Deglutition | 2 | 2022 | 202 | 0.070 |
Why?
|
| Physical Examination | 1 | 2012 | 1243 | 0.070 |
Why?
|
| Hand Strength | 3 | 2020 | 451 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 7074 | 0.070 |
Why?
|
| GTP-Binding Proteins | 1 | 2009 | 973 | 0.070 |
Why?
|
| Tuberculosis | 1 | 2017 | 1829 | 0.070 |
Why?
|
| Neurogenesis | 1 | 2011 | 833 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2011 | 19537 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2022 | 3750 | 0.070 |
Why?
|
| Mutation | 1 | 2009 | 29491 | 0.070 |
Why?
|
| Antipsychotic Agents | 1 | 1998 | 3071 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2012 | 1403 | 0.060 |
Why?
|
| Prednisone | 2 | 2021 | 1548 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 16404 | 0.060 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 1646 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2021 | 5728 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 5455 | 0.060 |
Why?
|
| Electrophysiology | 2 | 1996 | 1327 | 0.060 |
Why?
|
| Disability Evaluation | 2 | 2011 | 1826 | 0.060 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 58528 | 0.060 |
Why?
|
| Nerve Regeneration | 1 | 2009 | 802 | 0.060 |
Why?
|
| Sarcoma | 1 | 1994 | 1879 | 0.060 |
Why?
|
| Barium | 1 | 2022 | 64 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3160 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3278 | 0.050 |
Why?
|
| Fructose | 1 | 2003 | 296 | 0.050 |
Why?
|
| Breathing Exercises | 1 | 2020 | 51 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 2038 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2000 | 72 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 4312 | 0.050 |
Why?
|
| Respiration | 1 | 2006 | 1671 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2022 | 442 | 0.050 |
Why?
|
| Research Design | 2 | 2013 | 5883 | 0.050 |
Why?
|
| Respiratory Aspiration | 1 | 2020 | 84 | 0.050 |
Why?
|
| Time | 1 | 2021 | 529 | 0.050 |
Why?
|
| Serine C-Palmitoyltransferase | 1 | 2019 | 37 | 0.050 |
Why?
|
| Ulnar Nerve | 1 | 1999 | 110 | 0.040 |
Why?
|
| Median Nerve | 1 | 1999 | 127 | 0.040 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2011 | 1726 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2014 | 4286 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 39302 | 0.040 |
Why?
|
| Vitamin E Deficiency | 1 | 2017 | 37 | 0.040 |
Why?
|
| Physicians | 1 | 2015 | 4354 | 0.040 |
Why?
|
| Kidney Tubules | 1 | 2000 | 496 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 7486 | 0.040 |
Why?
|
| Sphingolipids | 1 | 2019 | 167 | 0.040 |
Why?
|
| Adolescent | 9 | 2019 | 85143 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 364 | 0.040 |
Why?
|
| Young Adult | 7 | 2020 | 56249 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 9597 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 1998 | 324 | 0.040 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2017 | 112 | 0.040 |
Why?
|
| Retrospective Studies | 8 | 2022 | 72608 | 0.040 |
Why?
|
| Sural Nerve | 1 | 1996 | 111 | 0.040 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2017 | 250 | 0.040 |
Why?
|
| Neurologic Examination | 1 | 2019 | 959 | 0.040 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 448 | 0.040 |
Why?
|
| Phonetics | 1 | 1996 | 192 | 0.040 |
Why?
|
| Time Factors | 7 | 2012 | 41094 | 0.030 |
Why?
|
| Botulinum Toxins | 1 | 1996 | 187 | 0.030 |
Why?
|
| Sensation | 1 | 1996 | 333 | 0.030 |
Why?
|
| Genotype | 1 | 2009 | 12923 | 0.030 |
Why?
|
| Patients | 1 | 2020 | 770 | 0.030 |
Why?
|
| Smad2 Protein | 1 | 2014 | 170 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2014 | 195 | 0.030 |
Why?
|
| Hand | 1 | 2019 | 861 | 0.030 |
Why?
|
| Activin Receptors, Type II | 1 | 2014 | 110 | 0.030 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2015 | 97 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2014 | 263 | 0.030 |
Why?
|
| Extremities | 1 | 2019 | 882 | 0.030 |
Why?
|
| Thigh | 1 | 2014 | 232 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 1997 | 601 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 971 | 0.030 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 1994 | 92 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2000 | 1933 | 0.030 |
Why?
|
| Elbow | 1 | 1993 | 152 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 11008 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 685 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1997 | 1146 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2021 | 1037 | 0.030 |
Why?
|
| Foot | 1 | 1996 | 510 | 0.030 |
Why?
|
| Accidents | 1 | 1993 | 168 | 0.030 |
Why?
|
| Infant | 4 | 2003 | 34574 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 1996 | 906 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2016 | 598 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 1635 | 0.030 |
Why?
|
| Hyperalgesia | 1 | 2016 | 501 | 0.030 |
Why?
|
| Genetic Linkage | 1 | 1998 | 2516 | 0.030 |
Why?
|
| Reaction Time | 1 | 1999 | 2138 | 0.030 |
Why?
|
| Vocal Cords | 1 | 1996 | 501 | 0.030 |
Why?
|
| Functional Laterality | 1 | 1999 | 2300 | 0.030 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 1329 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2009 | 8109 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 1692 | 0.030 |
Why?
|
| Arousal | 1 | 1997 | 1144 | 0.030 |
Why?
|
| Forearm | 1 | 1993 | 407 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 1957 | 0.030 |
Why?
|
| Anticonvulsants | 1 | 2021 | 1856 | 0.030 |
Why?
|
| Triglycerides | 1 | 1999 | 2591 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 8013 | 0.020 |
Why?
|
| Pandemics | 2 | 2020 | 7292 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 25281 | 0.020 |
Why?
|
| Psychometrics | 1 | 2019 | 2971 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2008 | 2678 | 0.020 |
Why?
|
| Cholesterol | 1 | 1999 | 2894 | 0.020 |
Why?
|
| Thromboembolism | 2 | 2008 | 986 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2017 | 744 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2014 | 2407 | 0.020 |
Why?
|
| Organ Size | 1 | 2014 | 2308 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2014 | 2298 | 0.020 |
Why?
|
| Peroneal Nerve | 1 | 2009 | 76 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2018 | 10542 | 0.020 |
Why?
|
| Quality of Life | 2 | 2006 | 11758 | 0.020 |
Why?
|
| ROC Curve | 1 | 2016 | 3532 | 0.020 |
Why?
|
| Self Report | 1 | 2019 | 3429 | 0.020 |
Why?
|
| Tongue | 1 | 2011 | 408 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2000 | 2977 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 1624 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 11276 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2016 | 2008 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2008 | 688 | 0.020 |
Why?
|
| Adjustment Disorders | 1 | 2006 | 71 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2006 | 6431 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 2119 | 0.020 |
Why?
|
| Data Collection | 1 | 2015 | 3314 | 0.020 |
Why?
|
| Marriage | 1 | 2006 | 314 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 1993 | 1462 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2008 | 400 | 0.020 |
Why?
|
| Life Tables | 1 | 2003 | 376 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2018 | 39891 | 0.020 |
Why?
|
| Registries | 1 | 2019 | 8095 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2014 | 8744 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 11777 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3703 | 0.010 |
Why?
|
| Models, Animal | 1 | 2009 | 2220 | 0.010 |
Why?
|
| Sleep | 1 | 1997 | 4222 | 0.010 |
Why?
|
| United States | 2 | 2022 | 67804 | 0.010 |
Why?
|
| Animals | 2 | 2010 | 170894 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2003 | 24744 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2006 | 3565 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1999 | 41221 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 2006 | 2046 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 1220 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2003 | 1250 | 0.010 |
Why?
|
| Recovery of Function | 1 | 2009 | 2951 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1998 | 310 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6777 | 0.010 |
Why?
|
| Asthma | 1 | 1996 | 5941 | 0.010 |
Why?
|
| Survival Rate | 1 | 2012 | 13262 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1998 | 374 | 0.010 |
Why?
|
| Pancuronium | 1 | 1996 | 46 | 0.010 |
Why?
|
| Vecuronium Bromide | 1 | 1996 | 34 | 0.010 |
Why?
|
| Atracurium | 1 | 1996 | 55 | 0.010 |
Why?
|
| Social Support | 1 | 2006 | 2120 | 0.010 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 1996 | 150 | 0.010 |
Why?
|
| Albuterol | 1 | 1996 | 211 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1996 | 400 | 0.010 |
Why?
|
| Child | 2 | 1999 | 74388 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 21811 | 0.010 |
Why?
|
| Bronchodilator Agents | 1 | 1996 | 509 | 0.010 |
Why?
|
| Anxiety | 1 | 2006 | 3924 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 2692 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2006 | 4161 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 15271 | 0.010 |
Why?
|
| Pedigree | 1 | 1998 | 4723 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 12416 | 0.010 |
Why?
|
| Risk Factors | 2 | 2008 | 70863 | 0.000 |
Why?
|
| Glucocorticoids | 1 | 1996 | 2108 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7177 | 0.000 |
Why?
|
| Incidence | 1 | 1996 | 20654 | 0.000 |
Why?
|